Vedolizumab Quantitation with Antibodies, Serum




Test Mnemonic

VEDOLZ

CPT Codes

  • 80280 - QTY (1)
  • 82397 - QTY (1)

Aliases

  • Entyvio

Includes

  • Vedolizumab QN, S
  • Vedolizumab Ab, S
  • VEMAB Interpretation

Performing Laboratory

Mayo Clinic Dpt of Lab Med & Pathology


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
1.5 mLSerumNo additive (Red) RefrigeratedAvoid multivitamins and dietary supplements containing biotin for 12 hours before collection. Nivolumab (Opdivo) must be discontinued at least 4 weeks prior to collection. Collect immediately before next scheduled dose (trough specimen). Separate serum from cells ASAP or within 2 hours of collection and transfer to standard aliquot tube.

Alternate Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
1.5 mLSerumSST (Gold) RefrigeratedAvoid multivitamins and dietary supplements containing biotin for 12 hours before collection. Nivolumab (Opdivo) must be discontinued at least 4 weeks prior to collection. Collect immediately before next scheduled dose (trough specimen). Separate serum from cells ASAP or within 2 hours of collection and transfer to standard aliquot tube.

Minimum Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
0.75 mL     

Stability

Environmental Condition Description
Refrigerated28 days
Frozen28 days
AmbientUnacceptable

Days Performed

Mon - Fri

Turnaround Time

6 - 9 days

Methodology

Name Description
Electrochemiluminescent Bridging Immunoassay 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 

Reference Range

Special Info

Avoid multivitamins and dietary supplements containing biotin for 12 hours before collection. Nivolumab (Opdivo) must be discontinued at least 4 weeks prior to collection. Collect immediately before next scheduled dose (trough specimen). This test is New York State approved.

Clinical Info

This test includes both quantitation and antibody testing. This test is useful in assessing for primary or secondary loss of response to therapy with vedolizumab, or as an aid to achieving desired serum concentrations of vedolizumab. The therapeutic thresholds for vedolizumab and optimal concentrations associated with good outcomes are not well established. Currently the American Gastroenterology Association does not have a formal guideline on optimal thresholds for vedolizumab.

Clinical Limitation

The presence of high concentrations of vedolizumab might inhibit the antibodies to vedolizumab (ATV) assay yielding false-negative results. Samples containing more than 100 ng/mL biotin (vitamin B7) may interfere with ATV (in the form of depressed signal) for VEMAB / Vedolizumab Antibodies, Serum.